Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer Symphony suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay. Together, these tests help physicians determine a patient’s individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials. For more information, visit www.agendia.com.
An Update on Agendia’s Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, I’d like to take a moment to reflect on Agendia’s recent achievements as a global leader in precision oncology and provide an update on forward-looking expansions that will have a positive impact on patients and their doctors.
Our mission is to provide best in class precision oncology tools, and we have seen year-over-year double-digit growth as more women than ever before are able to access the benefits of our MammaPrint and BluePrint tests – and this is just the beginning.
We achieved a major milestone last month when we announced a $35 million investment from Athyrium Capital Management. This financial partnership will help expand Agendia’s commercial footprint in the U.S. and internationally. It will also further the adoption of our next-generation sequencing-based MammaPrint BluePrint Kit and will facilitate investment in our Big Data programs that will help identify new biomarkers for breast cancer.
Our science continues to stand apart from the competition. Recent clinical data underscored the value of the landmark MINDACT trial and highlighted the role of MammaPrint in providing clear answers about the benefits of chemotherapy treatment for women of all ages. We were recognized in major international clinical practice guidelines for breast cancer treatment, and to this day, MammaPrint remains the only genomic test recommended for women with lymph node-positive disease by the American Society of Clinical Oncology (ASCO)
These recommendations, based on the results from the MINDACT trial, led to positive coverage decisions by major healthcare insurers in the U.S. We also identified opportunities for expanded adoption of our MammaPrint and BluePrint tests by hospitals and diagnostic labs around the world including most recently in France and Southeast Asia.
On the horizon, we anticipate exciting clinical developments from the FLEX, PRECiSE, I-SPY2 and MINDACT trials in the next year. We also plan to expand Agendia’s precision oncology pipeline through new collaborative research programs with leading academic institutions.
At Agendia, we believe it is the collective responsibility of the entire cancer care community to deliver precision oncology so we can minimize suffering and enable cancer patients to live the longest and healthiest lives possible. Our strength is in our data, our partnerships, and our commitment to our patients. I’m confident in our achievements as a company and look forward to what the future holds.